PubMed Health⌕ Search

PubMed · 7655724

Low-coherence interferometry in coronary arteries.

Abstract

LCI is an emerging intravascular diagnostic imaging technology. An LCI system could have a much higher resolution than intravascular ultrasound and may be capable of providing adequate diagnostic information about both geometry and morphology of diseased vessels. Soft plaque identification, thrombus detection, and assessment of the fibrotic cap covering the lesions may be possible. Fiber optic and micromechanical technologies involved in LCI provide an opportunity to build a very low-profile imaging catheter that can be incorporated into a guide wire and provide high-resolution imaging of the site of intervention before, during, and after intervention. Intravascular LCI is currently at a developmental stage with regard to its technology; so far no in-vivo measurements have been reported. It seems likely that the technical limitations can be overcome and that this will be an extremely useful diagnostic procedure in the future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V I Chornenky. 1995. Low-coherence interferometry in coronary arteries.. https://doi.org/10.1097/00019501-199505000-00004

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗